Side-by-side · Research reference

AdipotidevsCrystagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED15/49 cited

BAnimal-MechanisticHUMAN-REVIEWED12/40 cited

Adipotide

Pro-apoptotic Vascular-Targeting Peptide · Preclinical Only

PreclinicalStatus

PHB1TargetHossen 2013

ApoptosisMechanismHossen 2013

IV · Systemic · Preclinical Protocols OnlyHossen 2013

Crystagen

Khavinson Bioregulator · Immune-Thymic

B-cellPrimary targetСhervyakova 2014

SpleenTissue specificityСhervyakova 2014

AnimalEvidence level

SQ · Protocol variable

01Mechanism of Action

Parameter

Adipotide

Crystagen

Primary target

Prohibitin-1 (PHB1) on adipose vasculature endotheliumHossen 2013

B-lymphocytes in splenic tissueСhervyakova 2014

Pathway

CKGGRAKDC domain binds PHB1 → Peptide internalisation → D(KLAKLAK)₂ mitochondrial membrane disruption

B-cell activation → Immune modulation during agingСhervyakova 2014

Downstream effect

Endothelial apoptosis → Adipose vascular collapse → Adipocyte involution → Weight loss

B-cell activation via apoptosis reduction; no observed increase in splenic cell renewalСhervyakova 2014

Feedback intact?

N/A — Direct apoptotic mechanism, non-hormonal

Unknown — bioregulator mechanism not fully characterized

Origin

Synthetic bioconjugate: PHB1-targeting homing peptide + pro-apoptotic KLA sequence

Synthetic Lys-Glu-Asp-Gly tetrapeptide — Khavinson bioregulator series

Antibody development

—

02Dosage Protocols

Parameter

Adipotide

Crystagen

Animal dose (mouse)

Low dose (not specified in abstract)Hossen 2013

Systemic injection in diet-induced obesity (DIO) models.Hossen 2013

—

Route

Intravenous (systemic injection)

Subcutaneous (presumed from bioregulator class)

Frequency

Not specified in available data

Unknown — bioregulator protocols variable

Evidence basis

Preclinical animal models only

Animal / mechanistic

Human data

None — no clinical trials reported

—

Standard dose

—

Not standardized — variable protocols

Russian bioregulator literature does not specify unified human dosing.

Duration

—

Unknown — chronic administration presumed in animal models

Half-life

—

Not reported

03Metabolic / Fat Loss Evidence

Parameter

Adipotide

Crystagen

Primary fat target

White adipose tissue (all depots)

—

Mechanism

Vascular apoptosis → adipose blood supply collapse → adipocyte deathHossen 2013

—

Body weight reduction

Significant reduction in DIO miceHossen 2013

Absolute values not provided in abstract.

—

Leptin levels

Significant decrease

Parallel to adipose mass reduction.

—

Effect on adipocytes

Antiobesity effect on dysfunctional adipose cells (adipocytes + macrophages)Hossen 2013

—

Ectopic fat

Reduction in ectopic fat depositionHossen 2013

Marker of dysfunctional adipose tissue / metabolic syndrome.

—

Species tested

Obese rhesus monkeys, DIO mice

—

Human translation

Unknown — no clinical trials

—

04Side Effects & Safety

Parameter

Adipotide

Crystagen

Safety profile

Unknown — preclinical data only

—

Vascular selectivity

Targets adipose vasculature; off-target vascular effects unknown

—

Apoptotic mechanism risk

Pro-apoptotic payload may affect unintended tissues if selectivity incomplete

—

Kidney / liver toxicity

Not reported in available data

—

Immunogenicity

Not assessed in available data

—

Published adverse events

—

None reported in available animal literature

Human safety data

—

Absent — no controlled human trials identified

Autoimmune considerations

—

Theoretical concern with B-cell modulators in predisposed individuals

Absolute Contraindications

Adipotide

·Human use — not approved, no clinical safety data

Crystagen

·Active autoimmune disease (theoretical)

Relative Contraindications

Adipotide

·Any condition requiring intact adipose-tissue vascularisation

Crystagen

·Pregnancy / lactation (no data)
·Active B-cell malignancies

05Administration Protocol

Parameter

Adipotide

Crystagen

1. Route

Intravenous injection (systemic) in preclinical models. No human protocols exist.

Subcutaneous injection — presumed from bioregulator class convention. Specific anatomical sites not standardized.

2. Formulation

Bioconjugate peptide. May also be encapsulated in nanoparticles (prohibitin-targeted nanoparticle formulation, KLA-PTNP, showed superior efficacy vs. free bioconjugate in mice).Hossen 2013

Protocol not standardized. If lyophilized, sterile water or bacteriostatic saline typical for peptide bioregulators.

3. Preclinical dosing

Low-dose systemic injection (exact dosing not specified in available abstract). Frequency and duration not detailed.Hossen 2013

Not specified. Bioregulator protocols vary — some practitioners advocate evening dosing, others morning.

4. Storage

Not specified — likely requires peptide-grade lyophilised storage and reconstitution.

Lyophilized: room temperature, light-protected. Reconstituted: refrigerate, use within days to weeks depending on preservative.

06Stack Synergy

Adipotide

— no documented stacks

Crystagen

+ Vilon

Multi-pathway

View Vilon →

Vilon (Lys-Glu) activates T-helper cells via apoptosis reduction, while Crystagen activates B-cells. Dual T/B immune modulation in aging models may provide complementary thymic-immune support within the Khavinson bioregulator framework. Both target splenic immune aging through distinct lymphocyte subsets.

Crystagen: Dose unknown · SQ
Vilon: Dose unknown · SQ
Frequency: Protocol variable
Primary benefit: Broader thymic-immune coverage (T-cell + B-cell)

Сhervyakova 2014